科倫藥業(002422.SZ)一季度淨利潤預增50%-70%
格隆匯3月16日丨科倫藥業(002422.SZ)公佈,預計2022年第一季度歸屬於上市公司股東的淨利潤2.63億元–2.98億元,同比增長50%-70%;扣除非經常性損益後的淨利潤2.32億元-2.63億元,同比增長50%-70%。
業績變動原因:1.2022 年一季度,公司全力拓展輸液、非輸液製劑產品市場,持續優化產品結構,輸液、非輸液製劑產品銷售收入及毛利同比增長;
2.公司仿製藥持續放量,營業收入和毛利同比增長;
3.控股子公司伊犁川寧生物技術股份有限公司主要產品價格同比上漲,利潤同比增加;
4.公司整體融資利率下降,利息支出減少;同時,堅戈貶值,匯兑損失增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.